Active transport of imatinib into and out of cells: implications for drug resistance.
暂无分享,去创建一个
Munir Pirmohamed | M. Pirmohamed | R. Clark | Julia Thomas | Lihui Wang | Julia Thomas | Lihui Wang | Richard E Clark
[1] G. Ehninger,et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate , 2004, Leukemia.
[2] L. Ashman,et al. Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro. , 2003, Blood.
[3] Hiroshi Watanabe,et al. Interaction of Imatinib Mesilate with Human P-Glycoprotein , 2003, Journal of Pharmacology and Experimental Therapeutics.
[4] S. Khoo,et al. Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEMVBL, CEME1000, MDCKIIMRP1 and MDCKIIMRP2 cell lines , 2003 .
[5] T. Fojo,et al. The role of ABC transporters in clinical practice. , 2003, The oncologist.
[6] T. Buclin,et al. Functional consequence of MDR1 expression on imatinib intracellular concentrations. , 2003, Blood.
[7] T. Furukawa,et al. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells , 2003, Cancer science.
[8] Y. Awasthi,et al. Energy dependent transport of xenobiotics and its relevance to multidrug resistance. , 2003, Current cancer drug targets.
[9] G. Daley,et al. Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL , 2003, Cell.
[10] J. Melo,et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. , 2003, Blood.
[11] Francisco Cervantes,et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.
[12] W. Elmquist,et al. Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated Efflux , 2003, Journal of Pharmacology and Experimental Therapeutics.
[13] A. Schinkel,et al. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. , 2003, Advanced drug delivery reviews.
[14] R. Kim. Transporters and xenobiotic disposition. , 2002, Toxicology.
[15] H. Kantarjian,et al. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. , 2002, Cancer research.
[16] L. Campbell,et al. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration. , 2002, Cancer genetics and cytogenetics.
[17] Xin Lu,et al. Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. , 2002, Experimental hematology.
[18] B. Druker,et al. Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571* , 2002, The Journal of Biological Chemistry.
[19] R. Foà,et al. MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. , 2002, Blood.
[20] G. Kéri,et al. Interaction of tyrosine kinase inhibitors with the human multidrug transporter proteins, MDR1 and MRP1. , 2002, Biochimica et biophysica acta.
[21] Heinz Bönisch,et al. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3 , 2002, British journal of pharmacology.
[22] B. Druker,et al. STI571 (Gleevec) as a paradigm for cancer therapy. , 2002, Trends in molecular medicine.
[23] M. Baccarani,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.
[24] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[25] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[26] K. Giacomini,et al. Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. , 2001, Journal of pharmaceutical sciences.
[27] L. Ratner,et al. Multidrug resistance transporters and modulation , 2000, Current opinion in oncology.
[28] J. Melo,et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. , 2000, Blood.
[29] M. Kool,et al. Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport , 2000, British Journal of Cancer.
[30] G. Burckhardt,et al. Structure of renal organic anion and cation transporters. , 2000, American journal of physiology. Renal physiology.
[31] E. Hudson,et al. The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2). , 2000, Journal of cell science.
[32] M. Varella‐Garcia,et al. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. , 2000, Blood.
[33] O. Legrand,et al. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. , 1999, Blood.
[34] Z. Estrov,et al. The biology of chronic myeloid leukemia. , 1999, The New England journal of medicine.
[35] H K Kroemer,et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.
[36] E. Buchdunger,et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. , 1999, Journal of the National Cancer Institute.
[37] K. Giacomini,et al. Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). , 1998, The Journal of pharmacology and experimental therapeutics.
[38] M. Crouzet,et al. Effects of modulators of multidrug resistance on the expression of the MDR1 gene in human KB cells in culture , 1996, Anti-cancer drugs.
[39] I. Sánchez-García,et al. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[40] P. Sonneveld,et al. Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing themdr1 phenotype , 1992, Cancer Chemotherapy and Pharmacology.
[41] S. Khoo,et al. Expression of P-glycoprotein, multidrug-resistance proteins 1 and 2 in CEM, CEM(VBL), CEM(E1000), MDCKII(MRP1) and MDCKII(MRP2) cell lines. , 2003, AIDS.
[42] B. Druker,et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy , 2002, Leukemia.
[43] J. Gorski,et al. Induction of multidrug resistance-1 and cytochrome P450 mRNAs in human mononuclear cells by rifampin. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[44] M. Zucchetti,et al. Role of (cid:1) 1 Acid Glycoprotein in the In Vivo Resistance of Human BCR-ABL + Leukemic Cells to the Abl Inhibitor STI571 , 2000 .
[45] J. Tolan,et al. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. , 1999, Journal of pharmaceutical sciences.
[46] H. Koepsell,et al. Organic cation transporters in intestine, kidney, liver, and brain. , 1998, Annual review of physiology.
[47] T. Meyer,et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.